A new technique using patients’ own modified cells to treat Crohn’s disease has been proven to be effective in experiments using human cells, with a clinical trial of the treatment expected to start in the next six months.
Researchers at the NIHR Guy’s and St Thomas’ Biomedical Research Centre (BRC) developed the technique by studying white blood cells taken from patients who have Crohn’s disease, and comparing them to cells of healthy people. Their findings allowed cell therapy specialists in the BRC to develop a treatment involving taking patients’ cells, and growing them in a special culture so that they behave more like cells from healthy people.
The research, published in the journal Gastroenterology, shows that this technique is effective in human cells, meaning it is ready for use in a clinical trial. The proposed Tribute Trial will test whether the treatment is safe and effective for treating Crohn’s disease.
Crohn’s disease is a lifelong condition in which parts of the digestive system become severely inflamed, causing a range of symptoms such as diarrhoea, stomach aches, tiredness and weight loss. Its causes are unknown, but the immune system is known to play a part. The often debilitating condition is estimated to affect around 620,000 people in the UK.
Professor Graham Lord, previously Director of our BRC, led the research. He recently took up a role as Vice-President and Dean of the Faculty of Biology, Medicine and Health at the University of Manchester. He said:
“This is the next frontier in cell therapy, as we’re going beyond treating the symptoms of Crohn’s disease, and trying to reset the immune system to address the condition.
“It’s a real home-grown treatment in the sense that we started with observing cells and tissues donated by patients at Guy’s and St Thomas’, have developed a treatment, and are now starting to undertake trials, all at the Trust. It shows how central patients are to research, helping to create a treatment that might help thousands more people.”
Rachel Sawyer, a communications manager who is 50 and lives in Anerley in south east London, was diagnosed with Crohn’s disease in 2000 and treated at Guy’s and St Thomas’. Although her condition is now under control, she supports other people who have Crohn’s and runs the Twitter account @Bottomline_IBD.
She said: “One of the worst things for me was the unpredictability, particularly around needing the toilet in a hurry. Having Crohn’s completely re-routes your daily life and makes it hard to do the normal things most of us take for granted like going out socially or taking public transport. Even now, the fear of it is never really far from my mind.
“Another difficult thing is the stigma associated with bowel disease. It’s difficult to talk and be open about it, even with family and friends. I found life very isolating and challenging at times – and that’s something so many people with Crohn’s experience, regardless of whether they were diagnosed years ago or last month. For people diagnosed young, it can impact on the formative years of their life.
“Anything that could help people with Crohn’s have the confidence to go out and get back to being the people they were destined to be would be a game-changer.”
The researchers found that specialised white blood cells called regulatory T cells from Crohn’s patients produced less of a gut-specific protein called integrin ?4?7 than regulatory T cells from healthy people. Working with the specialists at the NIHR Guy’s and St Thomas’ BRC’s Advanced Therapies Manufacturing Platform, they developed a cell therapy technique based on these findings.
This technique involves developing cells from the Crohn’s disease patients with a molecule called RAR568, which restores healthy levels of integrin ?4?7. The cells are then given back to patients by intravenous infusion.
The Latest on: Crohn’s disease
via Google News
The Latest on: Crohn’s disease
- Crohn’s and Colitis Canada Awards $100,000 in Scholarships to Post-Secondary Students Through the 2021 AbbVie IBD Scholarship Programon August 24, 2021 at 11:14 am
Students living with Crohn’s disease or ulcerative colitis are heading back to class this fall with a scholarship that supports their academic and career goalsTORONTO, Aug. 24, 2021 (GLOBE NEWSWIRE) - ...
- Athos Therapeutics Announces Research Collaboration with Cleveland Clinic to Advance Precision Medicine in Inflammatory Bowel Diseaseon August 24, 2021 at 10:01 am
Athos Therapeutics, Inc., a late preclinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with immune-mediated diseases, announced today ...
- Theravance’s izencitinib fails in Phase IIb ulcerative colitis trialon August 24, 2021 at 4:15 am
Theravance Biopharma has reported that its drug candidate izencitinib (TD-1473) failed to meet the primary endpoint in Phase IIb dose-finding induction clinical trial to treat ulcerative colitis.
- Theravance drops one of two in J&J collab after JAK inhibitor's midstage ulcerative colitis failureon August 23, 2021 at 2:04 pm
Theravance Biopharma has one more chance for the Johnson & Johnson-partnered JAK inhibitor izencitinib after the therapy failed to alter symptoms of ulcerative colitis in a midstage test. The trial ...
- After landing in ICU and being fed through a tube, Lisa Neville raises awareness about Crohn’s diseaseon August 23, 2021 at 7:25 am
Senior Victorian Government Minister Lisa Neville wants to encourage open conversations about Crohn’s disease, and its invisible but chronic impact on lives.
- RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn'son August 23, 2021 at 4:10 am
TEL AVIV, Israel and RALEIGH, N.C., Aug. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ('RedHill' or the 'Company'), a specialty ...
- RedHill Announces Two New U.S. Patentson August 23, 2021 at 4:06 am
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn’s. U.S. patents for opaganib combination for the treatment of Ebola viru ...
- I live with IBS and Crohn’s Disease.on August 18, 2021 at 4:21 am
For people who live with Crohn's or Colitis alongside irritable bowel syndrome (IBS), it can be difficult to determine the cause of symptoms and, therefore, manage them. Franchesca tells us how she ...
- Strictly's Amy Dowden 'scared' for people to see her in hospital in doc on Crohn's diseaseon August 18, 2021 at 12:08 am
AMY DOWDEN has revealed that she's "scared" for people to watch the documentary about her battle with Crohn's disease, as it shows the Strictly Come Dancing star at her most "vulnerable".
- Strictly's Amy Dowden shows 'vulnerable' side in new documentary about her Crohn's disease battleon August 17, 2021 at 8:23 am
The ballroom beauty, 31, admitted it was challenging showing the harsh reality of her illness in her documentary Strictly Amy: Crohn's And Me, as she talked to RadioTimes on Tuesday.
via Bing News